

The Vaginal Microbiota and Influence of Select Probiotic Lactobacilli Strains

by Anthony Thomas, PhD

References

1. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. *Nature* 2012, 486:207-214.
2. Green KA, et al. Gynecologic health and disease in relation to the microbiome of the female reproductive tract. *Fertil Steril* 2015, 104:1351-1357.
3. Lewis FM, et al. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. *Obstet Gynecol* 2017, 129:643-654.
4. Petrova MI, et al. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. *Front Physiol* 2015, 6:81.
5. Kovachev SM. Obstetric and gynecological diseases and complications resulting from vaginal dysbacteriosis. *Microb Ecol* 2014, 68:173-184.
6. Dingens AS, et al. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. *BMC Pregnancy Childbirth* 2016, 16:278.
7. Wilson WA, et al. Regulation of glycogen metabolism in yeast and bacteria. *FEMS Microbiol Rev* 2010, 34:952-985.
8. O'Hanlon DE, et al. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. *PLoS One* 2013, 8:e80074.
9. Tachedjian G, et al. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. *Res Microbiol* 2017.
10. Boskey ER, et al. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. *Infect Immun* 1999, 67:5170-5175.
11. Boskey ER, et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. *Hum Reprod* 2001, 16:1809-1813.
12. Witkin SS, et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. *MBio* 2013, 4.
13. Conti C, et al. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. *J Physiol Pharmacol* 2009, 60 Suppl 6:19-26.
14. Graver MA, Wade JJ. The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth. *Ann Clin Microbiol Antimicrob* 2011, 10:8.
15. Juarez Tomas MS, et al. Growth and lactic acid production by vaginal Lactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli. *J Med Microbiol* 2003, 52:1117-1124.
16. Aldunate M, et al. Vaginal concentrations of lactic acid potentially inactivate HIV. *J Antimicrob Chemother* 2013, 68:2015-2025.
17. Owen DH, Katz DF. A vaginal fluid simulant. *Contraception* 1999, 59:91-95.
18. Aldunate M, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. *Front Physiol* 2015, 6:164.
19. Mossop H, et al. Influence of lactic acid on endogenous and viral RNA-induced immune mediator production by vaginal epithelial cells. *Obstet Gynecol* 2011, 118:840-846.
20. Haas R, et al. Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. *PLoS Biol* 2015, 13:e1002202.
21. Reid G, et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. *Nat Rev Microbiol* 2011, 9:27-38.
22. Ravel J, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 2011, 108 Suppl 1:4680-4687.
23. Gajer P, et al. Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012, 4:132ra152.
24. Zhou X, et al. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. *ISME J* 2007, 1:121-133.
25. Petricevic L, et al. Characterisation of the vaginal Lactobacillus microbiota associated with preterm delivery. *Sci Rep* 2014, 4:5136.
26. Lamont RF, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. *BJOG* 2011, 118:533-549.
27. Martin HL, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. *J Infect Dis* 1999, 180:1863-1868.
28. Hawes SE, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. *J Infect Dis* 1996, 174:1058-1063.
29. van de Wijgert JH, et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? *PLoS One* 2014, 9:e105998.
30. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. *BMC Infect Dis* 2015, 15:292.
31. Fettweis JM, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. *Microbiology* 2014, 160:2272-2282.
32. Fredricks DN, et al. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med* 2005, 353:1899-1911.

33. Fox C, Eichelberger K. Maternal microbiome and pregnancy outcomes. *Fertil Steril* 2015, 104:1358-1363.
34. MacIntyre DA, et al. The vaginal microbiome during pregnancy and the postpartum period in a European population. *Sci Rep* 2015, 5:8988.
35. Romero R, et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. *Microbiome* 2014, 2:4.
36. Kiss H, et al. Vaginal Lactobacillus microbiota of healthy women in the late first trimester of pregnancy. *BJOG* 2007, 114:1402-1407.
37. Brotman RM, et al. Microbiome, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections. *Vaccine* 2014, 32:1543-1552.
38. Mirmonsef P, et al. Free glycogen in vaginal fluids is associated with Lactobacillus colonization and low vaginal pH. *PLoS One* 2014, 9:e102467.
39. Farage M, Maibach H. Lifetime changes in the vulva and vagina. *Arch Gynecol Obstet* 2006, 273:195-202.
40. Nunn KL, Forney LJ. Unraveling the Dynamics of the Human Vaginal Microbiome. *Yale J Biol Med* 2016, 89:331-337.
41. Achilles SL, Hillier SL. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. *AIDS* 2013, 27 Suppl 1:S5-15.
42. Koumans EH, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. *Sex Transm Dis* 2007, 34:864-869.
43. Riggs M, et al. Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. *Sex Transm Dis* 2007, 34:954-959.
44. Vodstrcil LA, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. *PLoS One* 2013, 8:e73055.
45. Mayer BT, et al. Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis. *J Infect Dis* 2015, 212:793-802.
46. Schmitt C, et al. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. *Obstet Gynecol* 1992, 79:1020-1023.
47. Reid G, Bruce AW. Urogenital infections in women: can probiotics help? *Postgrad Med J* 2003, 79:428-432.
48. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. *Obstet Gynecol* 2007, 109:114-120.
49. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. *J Infect Dis* 2001, 183 Suppl 1:S1-4.
50. Denney JM, Culhane JF. Bacterial vaginosis: a problematic infection from both a perinatal and neonatal perspective. *Semin Fetal Neonatal Med* 2009, 14:200-203.
51. Hummelen R, et al. Deep sequencing of the vaginal microbiota of women with HIV. *PLoS One* 2010, 5:e12078.
52. Swidsinski A, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. *Am J Obstet Gynecol* 2008, 198:97 e91-96.
53. Donders GG, et al. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. *BJOG* 2002, 109:34-43.
54. Danese PN, et al. Biofilm formation as a developmental process. *Methods Enzymol* 2001, 336:19-26.
55. Hardy L, et al. Bacterial biofilms in the vagina. *Res Microbiol* 2017.
56. MacPhee RA, et al. Probiotic strategies for the treatment and prevention of bacterial vaginosis. *Expert Opin Pharmacother* 2010, 11:2985-2995.
57. Spurbeck RR, Arvidson CG. Lactobacilli at the front line of defense against vaginally acquired infections. *Future Microbiol* 2011, 6:567-582.
58. Anukam K, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. *Microbes Infect* 2006, 8:1450-1454.
59. Bruce AW, Reid G. Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. *Can J Microbiol* 1988, 34:339-343.
60. Reid G, et al. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. *FEMS Immunol Med Microbiol* 2001, 32:37-41.
61. Kontiokari T, et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. *BMJ* 2001, 322:1571.
62. Domig KJ, et al. Strategies for the evaluation and selection of potential vaginal probiotics from human sources: an exemplary study. *Benef Microbes* 2014, 5:263-272.
63. Weyers S, et al. Microflora of the penile skin-lined neovagina of transsexual women. *BMC Microbiol* 2009, 9:102.
64. Weyers S, et al. Cytology of the 'penile' neovagina in transsexual women. *Cytopathology* 2010, 21:111-115.
65. Kaufmann U, et al. Ability of an orally administered lactobacilli preparation to improve the quality of the neovaginal microflora in male to female transsexual women. *Eur J Obstet Gynecol Reprod Biol* 2014, 172:102-105.
66. Laue C, et al. Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial. *Benef Microbes* 2017:1-16.
67. Vedmedovska N, et al. Preventable maternal risk factors and association of genital infection with fetal growth restriction. *Gynecol Obstet*

- Invest* 2010, 70:291-298.
68. Jacobsson B, et al. Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis. *Acta Obstet Gynecol Scand* 2002, 81:1006-1010.
69. Anoshina TM. Role of microbiota correction in complex treatment of pregnant women with herpesvirus infection. *Perinatologiya i Pediatriya* 2016, 4:22-25.
70. Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference P. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. *Maturitas* 2014, 79:349-354.
71. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. *Am J Med Sci* 1997, 314:228-231.
72. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med* 1993, 329:753-756.
73. Krychman ML, Katz A. Breast cancer and sexuality: multi-modal treatment options. *J Sex Med* 2012, 9:5-13; quiz 14-15.
74. Marschalek J, et al. Influence of orally administered probiotic *Lactobacillus* strains on vaginal microbiota in women with breast cancer during chemotherapy: A randomized placebo-controlled double-blind pilot study. *Breast Care* 2017, 12:335-339.